Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer's Disease: a Systematic Review and Meta-analysis

Overview

Journal Int J Neuropsychopharmacol

Publisher Oxford University Press

Specialty Psychiatry

Date 2014 Dec 31

PMID 25548104

Citations 33

Authors

Shinji Matsunaga

Taro Kishi

Nakao Iwata

Affiliations

Soon will be listed here.

Abstract

Background: We performed an updated meta-analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease.

Methods: We reviewed cognitive function, activities of daily living, behavioral disturbance, global assessment, discontinuation rate, and individual side effects.

Results: Seven studies (total n=2182) were identified. Combination therapy significantly affected behavioral disturbance scores (standardized mean difference=-0.13), activity of daily living scores (standardized mean difference=-0.10), and global assessment scores (standardized mean difference=-0.15). In addition, cognitive function scores (standardized mean difference=-0.13, P=.06) exhibited favorable trends with combination therapy. The effects of combination therapy were more significant in the moderate-to-severe Alzheimer's disease subgroup in terms of all efficacy outcome scores. The discontinuation rate was similar in both groups, and there were no significant differences in individual side effects.

Conclusions: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer's disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated.

Citing Articles

Potential roles of lncRNA MALAT1-miRNA interactions in ocular diseases.

Nasrolahi A, Pour F, Salehi A, Kempisty B, Hajizadeh M, Feghhi M J Cell Commun Signal. 2023; 17(4):1203-1217.

PMID: 37870615 PMC: 10713964. DOI: 10.1007/s12079-023-00787-2.

The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.

Wright A, Lin G, Whittington M, Agboola F, Herron-Smith S, Rind D J Manag Care Spec Pharm. 2023; 29(9):1078-1083.

PMID: 37610113 PMC: 10512855. DOI: 10.18553/jmcp.2023.29.9.1078.

Neuroprotective Effect of Quercetin and Memantine against AlCl-Induced Neurotoxicity in Albino Wistar Rats.

Jadhav R, Kulkarni Y Molecules. 2023; 28(1).

PMID: 36615626 PMC: 9824229. DOI: 10.3390/molecules28010417.

The Potential Therapeutic Effects of Low-Dose Ionizing Radiation in Alzheimer's Disease.

Jebelli J, Hamper M, Van Quelef D, Caraballo D, Hartmann J, Kumi-Diaka J Cureus. 2022; 14(3):e23461.

PMID: 35371871 PMC: 8958987. DOI: 10.7759/cureus.23461.

Effect of Multiple Medicines on Dementia Initial Treatment: Experience and Thinking.

Gan J, Wang M, Liu S, Chen Z, Wang X, Ji Y Am J Alzheimers Dis Other Demen. 2021; 36:15333175211053134.

PMID: 34841902 PMC: 10581110. DOI: 10.1177/15333175211053134.

References

Bucks R, Ashworth D, Wilcock G, Siegfried K . Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing. 1996; 25(2):113-20. DOI: 10.1093/ageing/25.2.113. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

Cohn L, Becker B . How meta-analysis increases statistical power. Psychol Methods. 2003; 8(3):243-53. DOI: 10.1037/1082-989X.8.3.243. View

Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M . An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S33-9. View

Ametamey S, Bruehlmeier M, Kneifel S, Kokic M, Honer M, Arigoni M . PET studies of 18F-memantine in healthy volunteers. Nucl Med Biol. 2002; 29(2):227-31. DOI: 10.1016/s0969-8051(01)00293-1. View

Williams D, Wang J, Papke R . Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol. 2011; 82(8):915-30. PMC: 3162128. DOI: 10.1016/j.bcp.2011.05.001. View

Panisset M, Roudier M, Saxton J, Boller F . Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994; 51(1):41-5. DOI: 10.1001/archneur.1994.00540130067012. View

Cummings J, Mega M, Gray K, Carusi D, Gornbein J . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44(12):2308-14. DOI: 10.1212/wnl.44.12.2308. View

Jackson A, Nesic J, Groombridge C, Clowry O, Rusted J, Duka T . Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. Neuropsychopharmacology. 2008; 34(2):257-65. DOI: 10.1038/npp.2008.50. View

10.

Muayqil T, Camicioli R . Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias. Dement Geriatr Cogn Dis Extra. 2013; 2(1):546-72. PMC: 3522458. DOI: 10.1159/000343479. View

11.

Ittner L, Gotz J . Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011; 12(2):65-72. DOI: 10.1038/nrn2967. View

12.

Tariot P, Farlow M, Grossberg G, Graham S, McDonald S, Gergel I . Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317-24. DOI: 10.1001/jama.291.3.317. View

13.

Dysken M, Sano M, Asthana S, Vertrees J, Pallaki M, Llorente M . Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014; 311(1):33-44. PMC: 4109898. DOI: 10.1001/jama.2013.282834. View

14.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

15.

Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R . Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012; 366(10):893-903. DOI: 10.1056/NEJMoa1106668. View

16.

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

17.

Boada M, Arranz F . Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine. Dement Geriatr Cogn Disord. 2013; 35(1-2):23-33. DOI: 10.1159/000345989. View

18.

Cretu O, Szalontay A, Chirita R, Chirita V . [Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil]. Rev Med Chir Soc Med Nat Iasi. 2010; 112(3):641-5. View

19.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

20.

Hager K, Baseman A, Nye J, Brashear H, Han J, Sano M . Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Neuropsychiatr Dis Treat. 2014; 10:391-401. PMC: 3937252. DOI: 10.2147/NDT.S57909. View